Is BPC-157 worth trying?
If you have a specific tendon or joint injury that has plateaued on conservative management and you accept that the human evidence is thin, then yes, on a defined 4 to 6 week cycle. If you are taking it for general wellness, the cancer-pathway concern (BPC-157 promotes angiogenesis) is a poor trade against benefits unsupported by human trials.
Last reviewed · Panya.health editorial
What the evidence actually says
BPC-157 was isolated from human gastric juice by Predrag Sikiric's lab in Zagreb in the 1990s. The bulk of the evidence base is rodent: Chang 2014 in J Orthop Res showed enhanced tendon-to-bone healing in rats; Sikiric 2018 in Curr Pharm Des reviews ~30 years of preclinical work. Human data is limited to a small Phase 2 in inflammatory bowel disease and one Phase 2 in knee pain. The community framing is far ahead of the human evidence base. If you are reading 'BPC-157 is the most-studied peptide' and assuming that means human-validated, recalibrate.
When the trade is reasonable
Specific tendon or ligament injury (Achilles, rotator cuff, lateral epicondylitis, knee meniscus tear) that has plateaued on physical therapy + load management at 8 weeks. Subjective reports of acceleration are common in the recovery community; the rodent mechanism (angiogenesis + matrix remodelling at the injury site) is plausible. A 4 to 6 week cycle at 250 to 500 mcg/day subcutaneous, sometimes peri-injury, is the standard community protocol. Stop after the cycle. Reconstitution math: 5 mg vial in 2 to 5 mL bacteriostatic water, see panya.health/tools/reconstitution-calculator.
When the trade is bad
Active or recent cancer of any type. BPC-157 promotes angiogenesis, which is precisely what tumours need to grow. Anyone with a personal or family history of cancer driven by HGF/c-MET, VEGF, or similar pathways should not touch this. Pregnancy and breastfeeding: avoid. General wellness or longevity dosing without a specific injury: poor benefit-to-risk because the benefit case is thin and the long-term safety is uncharacterised. Cardiovascular safety in chronic use is unknown.
Where Panya stands
Panya documents BPC-157 at panya.health/peptide/bpc-157 with mechanism, evidence, dosing literature, and risk profile. We do NOT yet route to vendors for BPC-157 because non-GLP-1 vendor scoring is gated on lawyer review (research-chem regulatory exposure differs materially from prescription-grade telehealth). When that lands, BPC-157 vendor scorecards will use the same 11-signal rubric we apply to clinics. Until then, the community-mentioned vendors on the documentation page are listed without endorsement.
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.